<DOC>
	<DOC>NCT00916604</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.</brief_summary>
	<brief_title>To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male or female nonchildbearing potential Japanese T2DM patients, 3075 years. A body mass index (BMI) of 19 to 27 kg/m2. Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral antidiabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment. Renal dysfunction GFR &lt; 60 mL/min. Systolic pressure (SBP) &gt; 160 mmHg or diastolic pressure (DBP) &gt; 95 mmHg Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP. History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>AZD1656</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Multiple ascending doses</keyword>
	<keyword>Japanese</keyword>
	<keyword>T2DM</keyword>
</DOC>